Navigation Links
SEBM European Best Poster Prize awarded at Annual Conference of the German Society for Gene Therapy
Date:12/10/2010

Frauke Koenig, a PhD student in Professor Christoph Bruchle'd group, in the Department of Physical Chemistry at the Ludwig Maximilians University (LMU) Munich, was awarded this year's Society for Experimental Biology and Medicine European Prize for her work on live cell imaging of EGFR receptor targeting with short synthetic peptides. This multidisciplinary study was performed in collaboration with Professor Christoph Bruchle, Professor Ernst Wagner and Dr Manfred Oris's groups in the departments of Physical chemistry and Pharmacy at LMU.

The work selected for oral presentation was described at the 2010 Annual Conference of the German society for Gene Therapy, held in October in Munich. In this study live-cell imaging experiments were used to examine cellular internalization and trafficking of artificial gene vectors carrying a short peptide ligand, GE11, for specific targeting of EGF receptor positive cells.

Frauke Koenig said "EGF receptor is a promising target for selective gene therapy of cancer cells as it is overexpressed in many human tumors. Previous studies have shown that full-length EGF can be coupled to artificial gene vectors, such as polyplexes, resulting in their fast endocytosis into cancer cells. However full-length EGF has limitations for clinical application, as it is expensive in production, has a high tendency to aggregate and most importantly is able to activate the EGFR mediated mitogenic signaling cascades in the target cells. In this study polyplexes displaying GE11, a short peptide ligand with high affinity for the EGF receptor, provided a potential alternative for targeted cancer therapy. Highly sensitive fluorescence microscopy with high spatial and temporal resolution was employed to follow the cellular internalization of single polyplexes in real time". The presented data demonstrated slower kinetics of internalization for GE11 polyplexes, compared to EGF polyplexes. However, GE11 polyplexes provided considerable advantages for clinical applications, including higher transduction efficiency, lower aggregation and reduced mitogenic activity."

Presenting the award on behalf of the Society for Experimental Biology and Medicine, Professor Farzin Farzaneh (European Editor of Experimental Biology and Medicine), pointed out the therapeutic potential of receptor targeting not just for the tumor specific delivery of genes but also other therapeutic applications. This study also demonstrates the tremendous potential of live cell imaging as a tool for screening of candidate molecules for detailed analysis of molecular interactions and the identification of new drugs. The panel of Judges commended Ms Koenig for her outstanding work, its clear presentation and the stimulating discussion of broader implications of this study.


'/>"/>

Contact: Dr. Farzin Farzaneh
farzin.farzaneh@kcl.ac.uk
Society for Experimental Biology and Medicine
Source:Eurekalert

Related biology news :

1. European R&D leaders assembled in Tel Aviv will invest $70 million in joint R&D initiatives
2. Israeli Minister of Industry and Trade to address European R&D leaders in Tel Aviv
3. Transgenic corn suppresses European corn borer, saves farmers billions
4. Cellectis to Present at the Annual Congress of the European Society of Gene & Cell Therapy
5. Watch your seas: Marine scientists call for European marine observatory network
6. The European IVF Monitoring Group celebrates its 10-year anniversary
7. Awares Biometric Services Platform (BioSP) Deployed By a Large European Police Agency
8. VIB-UGent scientist Jiri Friml receives Koerber European Science Award 2010
9. European Society of Human Reproduction and Embryology Annual Meeting
10. European Alliance targets separation technologies for sustainable energy systems
11. Consumers in European countries appreciate grain healthiness in diverse ways
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017 ... by 2021, ABI Research identifies four technologies that ... solutions to secure significant share in the changing ... payments, and passive authentication.   "Companies ... it comes to security," says Dimitrios Pavlakis ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
(Date:3/27/2017)... ... March 27, 2017 , ... PMG Research is pleased to ... presented by The Conference Forum in Boston on April 3-4, 2017. The CTC conference ... clinical trial outcomes and bring them closer to the patient. Clinical Trial Collaborations also ...
(Date:3/27/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... today announced that it is now offering a 3 ... who want to have their DarioHealth products reimbursed by ... agreements with partners across the U.S. who will be ... will supply and bill the customer,s insurance for their ...
(Date:3/24/2017)... MOSCOW and ROCKVILLE, Md. ... portfolio company of Maxwell Biotech Venture Fund (MBVF), today ... of SQ109 added to the standard drug therapy regimen ... a new small molecule drug discovered by scientists at ... US National Institutes of Health. A ...
Breaking Biology Technology: